Accueil>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> Akt>>AKT Kinase Inhibitor

AKT Kinase Inhibitor

Catalog No.GC16366

L'inhibiteur de la kinase AKT est un inhibiteur de la kinase Akt avec une activité anti-tumorale[1].

Products are for research use only. Not for human use. We do not sell to patients.

AKT Kinase Inhibitor Chemical Structure

Cas No.: 842148-40-7

Taille Prix Stock Qté
10mM (in 1mL DMSO)
347,00 $US
En stock
5mg
315,00 $US
En stock
10mg
540,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

AKT Kinase Inhibitor is an Akt kinase inhibitor with anti-tumor activity[1].

The effect of selective inhibition of Akt in proliferating cells expressing Trop-2 is studied. Akt inhibition, either by silencing or with specific drugs, induces a marked decrease in cell proliferation in cells expressing Trop-2, in a dose-dependent fashion[1].

Trop-2 expressing tumors subcutaneously injected in animal models show a striking reduction of growth following treatment with specific drugs that inhibit Akt activity. Therefore Akt has a central functional role in mediating the Trop-2-dependent growth stimulus[1].

References:
[1]. Saverio Alberti, et al. Use of trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of cd9, akt and molecules of the tetraspanin signalling network. WO2013171777A2.

Avis

Review for AKT Kinase Inhibitor

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AKT Kinase Inhibitor

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.